| How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. | |
| | |
MedLine Citation:
|
PMID: 19564563 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The spiraling cost of cancer care, in particular the cost of cancer therapeutics that achieve only marginal benefits, is under increasing scrutiny. Although health-care professionals avoid putting a value on a life, our limited resources require that society address what counts as a benefit, the extent to which cost should factor in deliberations, and who should be involved in these decisions. Professional societies, such as the American Society of Clinical Oncology, government agencies, including the Food and Drug Administration, and insurance companies should be involved. However, no segment of society is better qualified to address these issues than the oncology community. Oncologists must offer clear guidance for the conduct of research, interpretation of results, and prescription of chemotherapies. We review recent drug approvals and clinical trials and comment on their relevance to the issue of the spiraling cost of oncology therapeutics. We suggest some standards that would serve as a starting point for addressing these issues. |
| | |
Authors:
|
Tito Fojo; Christine Grady |
Related Documents
:
|
11817383 - Ethical considerations on dynamic psychiatry and the tradition of relationship in psych... 21234573 - Editorial for anniversary issue of european radiology. 21348583 - New insights into tb from the 2010 european respiratory society annual conference. |
Publication Detail:
|
Type: Journal Article Date: 2009-06-29 |
Journal Detail:
|
Title: Journal of the National Cancer Institute Volume: 101 ISSN: 1460-2105 ISO Abbreviation: J. Natl. Cancer Inst. Publication Date: 2009 Aug |
Date Detail:
|
Created Date: 2009-08-05 Completed Date: 2009-08-10 Revised Date: 2010-09-27 |
Medline Journal Info:
|
Nlm Unique ID: 7503089 Medline TA: J Natl Cancer Inst Country: United States |
Other Details:
|
Languages: eng Pagination: 1044-8 Citation Subset: IM |
Affiliation:
|
Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA. tfojo@helix.nih.gov |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies, Monoclonal
/
economics,
therapeutic use Antineoplastic Agents / economics*, therapeutic use* Antineoplastic Combined Chemotherapy Protocols / economics, therapeutic use Carcinoma, Non-Small-Cell Lung / drug therapy, economics Clinical Trials, Phase III as Topic Cost-Benefit Analysis* Disease-Free Survival* Drug Approval Drug Costs* Drug Industry / economics Humans Lung Neoplasms / drug therapy, economics Neoplasms / drug therapy*, economics* Public Opinion Quality-Adjusted Life Years Receptor, Epidermal Growth Factor / drug effects Survival Analysis Treatment Outcome United States United States Food and Drug Administration Value of Life* |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Antineoplastic Agents; 0/cetuximab; EC 2.7.10.1/Receptor, Epidermal Growth Factor |
| Comments/Corrections | |
Comment In:
|
J Natl Cancer Inst. 2010 Aug 4;102(15):1207; author reply 1207-10
[PMID:
20651322
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Comparison of inflammatory response after implantation of sirolimus- and Paclitaxel-eluting stents i...
Next Document: DAMPs and inflammatory processes: the role of redox in the different outcomes.